University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 5C-19-1


A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects with Metastatic or Locally Advanced Solid Tumors, with Expansion to Select Solid Tumors

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Koji Matsuo, M.D.
Other Trial Staff:  

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.